PQS Implementation: Unterschied zwischen den Versionen

Aus cannabis.gmpvintern.de
Zur Navigation springen Zur Suche springen
(Die Seite wurde neu angelegt: „In addition to the above general statements on PQS, Chapter 1 of the EU GMP Guidelines (see RegLink Chapter 1 PQS) contains specific information on GMP for med…“)
 
 
Zeile 37: Zeile 37:
  
 
There is no doubt that Chapter 1 of the EU GMP Guide contains historically evolved redundancies - within the chapter itself and in relation to other chap-ters and the Annex to the guideline. This makes reading this chapter a little tedious at times. However, the selected aspects of GMP mentioned in Chapter 1 demonstrate in a practical way that the previously described PQS elements are not an end in themselves. Instead, the PQS, as described in Chapter 1 of the EU GMP Guidelines, should serve a single purpose. The pharmaceutical quality system should ensure that the quality of the medicinal products meets the requirements defined in the pharmacopoeia or marketing authorisation, that they are safe and effective and, as a result, guarantee the safety of the patient.
 
There is no doubt that Chapter 1 of the EU GMP Guide contains historically evolved redundancies - within the chapter itself and in relation to other chap-ters and the Annex to the guideline. This makes reading this chapter a little tedious at times. However, the selected aspects of GMP mentioned in Chapter 1 demonstrate in a practical way that the previously described PQS elements are not an end in themselves. Instead, the PQS, as described in Chapter 1 of the EU GMP Guidelines, should serve a single purpose. The pharmaceutical quality system should ensure that the quality of the medicinal products meets the requirements defined in the pharmacopoeia or marketing authorisation, that they are safe and effective and, as a result, guarantee the safety of the patient.
 +
 +
== Links ==
 +
* [[Design of a pharmaceutical quality system (PQS)]]
 +
* [[Quality policy, planning and objectives in the PQS]]
 +
* [[Resources to develop, implement and maintain a PQS]]
 +
* [[PQS tools]]

Aktuelle Version vom 19. Mai 2023, 19:13 Uhr

In addition to the above general statements on PQS, Chapter 1 of the EU GMP Guidelines (see RegLink Chapter 1 PQS) contains specific information on GMP for medicinal products and quality control. At first glance, this content appears to be the same as the requirements in the rest of the chapter and the Annexes of the EU GMP Guidelines and therefore redundant. For example, it states that the analytical methods and critical stages (e.g. drying of cannabis flowers) of the manufacturing process must be validated. It also requires that procedures be in place to monitor outsourced activities.

It also states that the sampling process must only be carried out by authorised personnel. It is well known that the same requirements are detailed in Annex 15 (see Chapter C.4.15 Annex 15: Qualification and Validation) and Chapter 7 or Chapter 6 (see Chapter C.3.1.7 Chapter 7: Outsourced Activities and Chap-ter C.3.1.6 Chapter 6: Quality Control) of the EU GMP Guidelines - together with a number of other requirements not explicitly included in Chapter 1 of the Guidelines. Why does Chapter 1 highlight certain aspects of GMP?

This question is quickly answered when the points explicitly mentioned in Chapter 1 of the EU GMP Guidelines are listed in a chronological order that corresponds to the manufacturing process chain of a medicinal product. From this point of view, these aspects clearly illustrate how a pharmaceutical plant uses a functioning PQS to achieve a situation that is also described as a state of control (ICH Q10), see Figure 4.

Table 1: State of Control in the PQS

State of control in the PQS
ICH Q10, glossary "State of Control":

A condition in which the set of controls consistently provides assurance of continued process performance and product quality.

EU GMP Guidelines, Chapter 1, Section 1.4 (viii):

A state of control is established and maintained by developing and using effective monitoring and control systems for process performance and product quality.

When broken down to the individual steps in the manufacture of medicinal products, this means the following (the sections in brackets refer to the corre-sponding requirements listed in Chapter 1 of the EU GMP Guidelines)

  • Appropriate resources (premises, equipment, facilities, personnel) are available. (1.8 iii and 1.9 i)
  • Medicinal products are designed and developed taking into account the requirements of good manufacturing practice. (1.4 iii)
  • All manufacturing processes are clearly defined, systematically reviewed in the light of experience, and demonstrated to be capable of consistent-ly producing medicinal products of the required quality and in accordance with their specifications. (1.8 i)
  • Critical steps in the manufacturing process and significant changes in the process are validated. (1.8 ii)
  • Arrangements are made for the production and use of appropriate start-ing materials and packaging materials, and it is ensured that they are supplied by qualified suppliers. (1.4 vi)
  • All necessary controls on intermediates and bulk materials and all other in-process controls and validations are carried out. (1.4 x).
  • Samples of these products are taken by approved personnel and methods. (1.9 ii)
  • The test methods used are validated. (1.9 iii)
  • The finished products so produced are of the required purity, in their appropriate containers and correctly labelled. (1.9 v)
  • Sufficient reference samples are retained. (1.9 viii)
  • Medicinal products are not released prior to certification by a Qualified Person. (1.4 xv, 1.9 vii)
  • Good Distribution Practice (GDP) is implemented: Medicinal products are stored and distributed in such a way that their quality is maintained throughout their shelf-life and any quality risk is minimised. (1.4 xvi, 1.8 ix)
  • All complaints and significant deviations are recorded, investigated to determine the root cause, and appropriate corrective and preventive ac-tions are defined and implemented. (1.8 vii and 1.8 xi)
  • A product recall system is in place. (1.8 x)

In addition, sections 1.8 iv-vi and 1.8 viii, 1.9 iv and 1.9 vi of Chapter 1 of the EU GMP Guidelines contain further general requirements. These relate to the necessary records, training of personnel and the correct implementation of the specified procedures. Procedures must also be in place for the management of outsourced activities [1.4 vii].

There is no doubt that Chapter 1 of the EU GMP Guide contains historically evolved redundancies - within the chapter itself and in relation to other chap-ters and the Annex to the guideline. This makes reading this chapter a little tedious at times. However, the selected aspects of GMP mentioned in Chapter 1 demonstrate in a practical way that the previously described PQS elements are not an end in themselves. Instead, the PQS, as described in Chapter 1 of the EU GMP Guidelines, should serve a single purpose. The pharmaceutical quality system should ensure that the quality of the medicinal products meets the requirements defined in the pharmacopoeia or marketing authorisation, that they are safe and effective and, as a result, guarantee the safety of the patient.

Links[Bearbeiten]